Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Life expectancy greater than or equal to (>=3) months

• For women who are not postmenopausal or surgically sterile, agreement to remainabstinent or use single or combined contraceptive methods that result in a failurerate of less than (<) 1 percent (%) per year during the treatment period and for atleast 6 months after the last dose of study drug

• Distant metastatic, recurrent or persistent squamous cell carcinoma, adenosquamouscarcinoma or adenocarcinoma of the cervix that is not amenable to curative treatmentwith surgery and/or radiation therapy

• Either measurable or non-measurable disease. If disease is non-measurable or limitedto the radiation field, a biopsy or fine-needle aspiration is required to confirmmalignancy

• Eligible for carboplatin and paclitaxel chemotherapy in accordance with localstandards of care

• Adequate hematological, renal and hepatic function

• Normal blood coagulation parameters

• Recovered (to Grade less than or equal to [<=] 1) from the effects of prior surgery,radiation therapy or chemoradiotherapy

Exclusion Criteria:

• Pregnant or lactating

• History of other malignancy within 5 years before screening, except for non-melanomaskin carcinoma

• Ongoing disease involving the bladder or rectum at screening/baseline. In participantswith pelvic disease, absence of tumor in the bladder or rectal mucosa must bedemonstrated by magnetic resonance imaging (MRI) (preferred method, orendoscopy/cystoscopy if MRI is not easily accessible) within 28 days before enrolment

• Evidence of abdominal free air

• Bilateral hydronephrosis

• Untreated central nervous system (CNS) metastases

• Prior chemotherapy for recurrent, persistent or metastatic cervical cancer. Prioradjuvant or neoadjuvant chemotherapy for Stage I-IVA disease (i.e. for non-metastaticdisease) is permitted if completed greater than (>) 6 months before first study dose

• Prior chemoradiation within the 3 months preceding first study dose

• Prior radiotherapy delivered using cobalt

• Prior or current bevacizumab or other anti-angiogenic treatment

• Requirement for treatment with any medicinal product that contraindicates the use ofany of the study drugs, may interfere with the planned treatment, affects participantcompliance or puts the participant at high risk for treatment-related complications

• Treatment with another investigational agent within 28 days or 2 investigational agenthalf-lives before first study dose

• Major surgical procedure, open biopsy or significant traumatic injury within 28 daysbefore the first dose of bevacizumab or anticipation of the need for major surgeryduring the course of study treatment

• Minor surgical procedure within 2 days before the first dose of study drug

• Any prior history of fistula or GI perforation

• Known hypersensitivity to bevacizumab or any of its excipients, Chinese hamster ovarycell products or other recombinant human or humanized antibodies to any plannedchemotherapy

• Active GI bleeding or ulcer

• Uncontrolled hypertension

• Clinically significant active cardiovascular disease

• National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)Version 4.0, Grade greater than or equal to (>=) 2 peripheral vascular disease